Merck, Cidara Therapeutics see US FTC grant early termination for $9.2bn deal
By Wesley Brown ( December 19, 2025, 22:40 GMT | Insight) -- Merck and Cidara Therapeutics were granted early termination of the applicable Hart-Scott-Rodino Act waiting period by the US Federal Trade Commission on Friday, according to a securities filing. The $9.2 billion acquisition by Merck was announced on Nov. 14 and sees the pharmaceutical heavyweight acquire Cidara, a flu antiviral medicine developer.Merck and Cidara Therapeutics were granted early termination of the applicable Hart-Scott-Rodino Act waiting period by the US Federal Trade Commission on Friday, according to a securities filing....
Prepare for tomorrow’s regulatory change, today
MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.
Know what others in the room don’t, with features including:
- Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
- Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
- Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
- Curated case files bringing together news, analysis and source documents in a single timeline
Experience MLex today with a 14-day free trial.